Clinical trials: ADHF
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF.
- Trial name
- CAT-HF (NCT01953874)
- Testing
- MV ASV, Optimized Medical Treatment
- Where
- 15 sites in United States, Germany
- Volunteers
- 126 people
- Sponsor
- ResMed
Hyponatremia, Acute Decompensated Heart Failure
Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)
This study will evaluate the safety and effectiveness of Conivaptan, a vasopressin antagonist, in the treatment of hyponatremic subjects having symptomatic acute decompensated heart failure (ADHF).
- Trial name
- CONVERT-H (NCT00843986)
- Testing
- conivaptan
- Where
- 4 sites in India
- Volunteers
- 9 people
- Sponsor
- Cumberland Pharmaceuticals
Acute Decompensated Heart Failure
Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.
- Trial name
- ABC-HFT (NCT00842023)
- Testing
- Nesiritide, Nitroglycerin
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Western University of Health Sciences
Heart Failure Acute, Heart Failure，Congestive
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide.
- Conditions
- Heart Failure Acute, Heart Failure，Congestive, Heart Failure; With Decompensation
- Trial name
- EMPA-RESPONSE (NCT03200860)
- Testing
- Empagliflozin 10 MG
- Where
- 5 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- University Medical Center Groningen
Acute Decompensated Heart Failure
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute decompensated heart failure.
- Trial name
- NCT05346653
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Acute Decompensated Heart Failure
REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)
The purpose of this observational study is to collect and characterize multiple physiologic data from a broad subset of subjects with acute heart failure (HF) Changes in physiologic data are expected to correlate with 30-day…
- Trial name
- READMIT-HF (NCT01574144)
- Testing
- AVIVO™ PiiX Patch Monitor System
- Where
- 8 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Decompensated Heart Failure
Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics
The purpose of this research study is to compare the effects (good and bad) of ultrafiltration treatment with standard intravenous (in your vein) diuretic therapy (furosemide, torsemide, bumetanide) on your heart function and…
- Trial name
- NCT01457053
- Testing
- Loop diuretics (furosemide, torsemide, bumetanide), Ultrafiltration
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Cincinnati
Acute Heart Failure, Decompensated Heart Failure
Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study
To determine if a strategy of early discharge using a novel subcutaneous delivery system for parenteral furosemide can improve clinical outcomes within 30 days of randomization (days alive and outside the hospital) compared to…
- Trial name
- SUBQ-HF (NCT03170219)
- Testing
- subcutaneous furosemide and sc2wear device
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- Adrian Hernandez
Acute Decompensated Heart Failure
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.
- Trial name
- NCT04318093
- Testing
- BMS-986259
- Where
- 18 sites in Argentina, Czechia and 4 more
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure, Cardiac Failure
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment
The purpose of the research is to determine if patients have fewer Heart Failure (HF) events after receiving Aquapheresis (AQ) therapy compared to intravenous (IV) diuretics up to 90 days of discharge from the hospital.
- Conditions
- Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
- Trial name
- AVOID-HF (NCT01474200)
- Testing
- Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
- Where
- 38 sites in United States
- Volunteers
- 224 people
- Sponsor
- Nuwellis, Inc.
Acute Decompensated Heart Failure, Acute Kidney Injury
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics.
- Trial name
- AKINESIS (NCT01291836)
- Where
- 13 sites in United States, Greece and 5 more
- Volunteers
- 930 people
- Sponsor
- Alere San Diego
Acute Decompensated Heart Failure
A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients
REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients, is a multicenter, randomized, attention-controlled, single-blind trial designed to examine the hypothesis that, in addition to standard care, a…
- Trial name
- REHAB-HF (NCT02196038)
- Testing
- multi-domain rehabilitation intervention, Attention Control
- Where
- 3 sites in United States
- Volunteers
- 349 people
- Sponsor
- Wake Forest University Health Sciences